Literature DB >> 20470859

VE-cadherin and PECAM-1 enhance ALL migration across brain microvascular endothelial cell monolayers.

Stephen M Akers1, Heather A O'Leary, Fred L Minnear, Michael D Craig, Jeffrey A Vos, James E Coad, Laura F Gibson.   

Abstract

OBJECTIVE: Infiltration of the central nervous system (CNS) by leukemia is a problematic disease manifestation of acute lymphoblastic leukemia (ALL). The mechanisms by which leukocytes interact with human brain-derived microvasculature endothelial cells (HBMEC) and enter the CNS are largely derived from models of inflammation. However, our data indicate that ALL cells do not elicit an inflammatory phenotype by HBMEC. Our current investigation focuses on the contribution of the unique coexpression of vascular endothelial (VE)-cadherin and platelet endothelial cell adhesion molecule-1 (PECAM-1) by ALL in mediating leukemic cell interactions with HBMEC as an in vitro model of the blood-brain barrier.
MATERIALS AND METHODS: Primary ALL and ALL cell lines were evaluated for VE-cadherin and PECAM-1 expression. Lentiviral-mediated transduction of VE-cadherin and PECAM-1 into REH cells and antibody neutralization of VE-cadherin and PECAM-1 in SUP-B15 cells was used to delineate the role of these two proteins in mediating ALL adhesion to, and migration through, HBMEC monolayers.
RESULTS: Although cell line models indicate that VE-cadherin and PECAM-1 expression is found on the surface Philadelphia chromosome-positive ALL, evaluation of primary ALL demonstrates that VE-cadherin and PECAM-1 are expressed independent of Philadelphia status. Expression of VE-cadherin and PECAM-1 by ALL enhanced the adhesion of ALL to HBMEC, while expression of PECAM-1 enhanced ALL adhesion to, and migration through, HBMEC.
CONCLUSIONS: Expression of VE-cadherin and PECAM-1 by ALL cells positions them to interact with HBMEC. By increasing our understanding of molecular mechanisms through which ALL cells gain entry into the CNS, new strategies may be designed to prevent leukemia cell entry into the CNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470859      PMCID: PMC2929642          DOI: 10.1016/j.exphem.2010.05.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Determinants of human B cell migration across brain endothelial cells.

Authors:  Andrea Alter; Martin Duddy; Sherry Hebert; Katarzyna Biernacki; Alexandre Prat; Jack P Antel; Voon Wee Yong; Robert K Nuttall; Caroline J Pennington; Dylan R Edwards; Amit Bar-Or
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

Review 3.  Three or more routes for leukocyte migration into the central nervous system.

Authors:  Richard M Ransohoff; Pia Kivisäkk; Grahame Kidd
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

4.  Molecular anatomy of interendothelial junctions in human blood-brain barrier microvessels.

Authors:  Andrzej W Vorbrodt; Danuta H Dobrogowska
Journal:  Folia Histochem Cytobiol       Date:  2004       Impact factor: 1.698

5.  Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is associated with a naïve B-cell phenotype in human tonsils.

Authors:  D E Jackson; L M Gully; T L Henshall; C E Mardell; P J Macardle
Journal:  Tissue Antigens       Date:  2000-08

Review 6.  Molecular plasticity of human melanoma cells.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Angela R Hess; Richard E B Seftor
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

Review 7.  Brain-metastatic melanoma: a neurotrophic perspective.

Authors:  Dario Marchetti; Yvonne Denkins; Jane Reiland; Andrea Greiter-Wilke; Jennifer Galjour; Brian Murry; Jason Blust; Madhuchhanda Roy
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

8.  Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Authors:  Heike Pfeifer; Barbara Wassmann; Wolf-Karsten Hofmann; Martina Komor; Urban Scheuring; Patrick Brück; Anja Binckebanck; Eberhard Schleyer; Nicola Gökbuget; Thomas Wolff; Michael Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

Review 9.  Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis.

Authors:  Gianfranco Bazzoni; Elisabetta Dejana
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

10.  Human brain microvascular endothelial cells and umbilical vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration.

Authors:  Shumei Man; Eroboghene E Ubogu; Katherine A Williams; Barbara Tucky; Melissa K Callahan; Richard M Ransohoff
Journal:  Clin Dev Immunol       Date:  2008
View more
  17 in total

Review 1.  Central nervous system niche involvement in the leukemia.

Authors:  N Heidari; N Saki; L De Filippis; M Shahjahani; A Teimouri; A Ahmadzadeh
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

Review 2.  Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies.

Authors:  Soumit K Basu; Scot C Remick; Manish Monga; Laura F Gibson
Journal:  Clin Exp Metastasis       Date:  2013-12-05       Impact factor: 5.150

3.  PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Authors:  Nan Wu; Tetsuya Kurosu; Gaku Oshikawa; Toshikage Nagao; Osamu Miura
Journal:  Int J Oncol       Date:  2012-12-06       Impact factor: 5.650

4.  The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression.

Authors:  Gerhard Fuka; Maximilian Kauer; Reinhard Kofler; Oskar A Haas; Renate Panzer-Grümayer
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

5.  Pro-inflammatory TNFα and IL-1β differentially regulate the inflammatory phenotype of brain microvascular endothelial cells.

Authors:  Simon J O'Carroll; Dan Ting Kho; Rachael Wiltshire; Vicky Nelson; Odunayo Rotimi; Rebecca Johnson; Catherine E Angel; E Scott Graham
Journal:  J Neuroinflammation       Date:  2015-07-08       Impact factor: 8.322

Review 6.  The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Nathan P Gossai; Peter M Gordon
Journal:  Front Pediatr       Date:  2017-04-26       Impact factor: 3.418

7.  Cytotoxic effects of docetaxel as a candidate drug of drug-eluting stent on human umbilical vein endothelial cells and the signaling pathway of cell migration inhibition, adhesion delay and shape change.

Authors:  Tingzhang Hu; Chun Yang; Meiling Fu; Jiali Yang; Rolin Du; Xiaolin Ran; Tieying Yin; Guixue Wang
Journal:  Regen Biomater       Date:  2017-05-05

8.  Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.

Authors:  Soo-Hyun Kim; Richard P Redvers; Lap Hing Chi; Xiawei Ling; Andrew J Lucke; Robert C Reid; David P Fairlie; Ana Carolina Baptista Moreno Martin; Robin L Anderson; Delphine Denoyer; Normand Pouliot
Journal:  Dis Model Mech       Date:  2018-07-06       Impact factor: 5.758

Review 9.  Platelet Endothelial Cell Adhesion Molecule-1 and Oligodendrogenesis: Significance in Alcohol Use Disorders.

Authors:  Chitra D Mandyam; Emmanuel G Villalpando; Noah L Steiner; Leon W Quach; McKenzie J Fannon; Sucharita S Somkuwar
Journal:  Brain Sci       Date:  2017-10-16

10.  SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells.

Authors:  Sara Cuvertino; Genny Filiciotto; Ashish Masurekar; Vaskar Saha; Georges Lacaud; Valerie Kouskoff
Journal:  Oncotarget       Date:  2016-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.